Next Article in Journal
Prognostic Value of the Conversion to a Shockable Rhythm in Out-of-Hospital Cardiac Arrest Patients with Initial Non-Shockable Rhythm
Next Article in Special Issue
Correlation between Transthoracic Lung Ultrasound Score and HRCT Features in Patients with Interstitial Lung Diseases
Previous Article in Journal
Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells
Previous Article in Special Issue
High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology
Open AccessArticle

Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank

1
European IPF Registry & Biobank (eurIPFreg/bank), 35394 Giessen, Germany
2
Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), 35394 Giessen, Germany
3
Agaplesion Lung Clinic, 35753 Greifenstein, Germany
4
Cardio-Pulmonary Institute (CPI), EXC 2026, Project ID: 390649896, Justus-Liebig University Giessen, 35394 Giessen, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(5), 643; https://doi.org/10.3390/jcm8050643
Received: 5 April 2019 / Revised: 26 April 2019 / Accepted: 4 May 2019 / Published: 9 May 2019
(This article belongs to the Special Issue The New Frontier in Pulmonary Fibrosis)
Background: New biomarkers are urgently needed to facilitate diagnosis in Interstitial Lung Diseases (ILD), thus reducing the need for invasive procedures, and to enable tailoring and monitoring of medical treatment. Methods: In this study we investigated if patients with idiopathic pulmonary fibrosis (IPF; n = 21), non-IPF ILDs (n = 57) and other lung diseases (chronic obstructive pulmonary disease (COPD) n = 24, lung cancer (LC) n = 16) as well as healthy subjects (n = 20) show relevant differences in exhaled NO (FeNO; Niox MINO), or in eicosanoid (PGE2, 8-isoprostane; enzyme-linked immunosorbent assay (ELISA)) levels as measured in exhaled breath condensates (EBC) and bronchoalveolar lavage fluids (BALF). Results: There was no significant difference in FeNO values between IPF, non-IPF ILDs and healthy subjects, although some individual patients showed highly elevated FeNO. On the basis of the FeNO signal, it was neither possible to differentiate between the kind of disease nor to detect exacerbations. In addition, there was no correlation between FeNO values and lung function. The investigation of the eicosanoids in EBCs was challenging (PGE2) or unreliable (8-isoprostane), but worked out well in BALF. A significant increase of free 8-isoprostane was observed in BALF, but not in EBCs, of patients with IPF, hypersensitivity pneumonitis (HP) and sarcoidosis, possibly indicating severity of oxidative stress. Conclusions: FeNO-measurements are not of diagnostic benefit in different ILDs including IPF. The same holds true for PGE2 and 8-isoprostane in EBC by ELISA. View Full-Text
Keywords: idiopathic pulmonary fibrosis (IPF); exhalative breath markers; European Registry for idiopathic pulmonary fibrosis (eurIPFreg); interstitial lung diseases (ILD) idiopathic pulmonary fibrosis (IPF); exhalative breath markers; European Registry for idiopathic pulmonary fibrosis (eurIPFreg); interstitial lung diseases (ILD)
Show Figures

Figure 1

MDPI and ACS Style

Krauss, E.; Froehler, M.; Degen, M.; Mahavadi, P.; Dartsch, R.C.; Korfei, M.; Ruppert, C.; Seeger, W.; Guenther, A. Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank. J. Clin. Med. 2019, 8, 643.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop